One To Watch

Sciwind Biosciences

A China-based biotechnology company developing peptide and small-molecule therapeutics for metabolic diseases, particularly obesity and type II diabetes. Sciwind Biosciences focuses on incretin-based therapies targeting GLP-1 and related pathways.

Company Overview

Sciwind Biosciences develops medicines aimed at treating metabolic diseases such as obesity, type II diabetes and related conditions. The company’s strategy centers on incretin-based therapies designed to improve metabolic regulation and weight management.

Its pipeline includes injectable and oral drug candidates targeting GLP-1 and related receptors. Several programs are built on proprietary peptide engineering and drug-delivery technologies designed to support long-acting or oral formulations.

Headquarters and Global Presence

Sciwind Biosciences is headquartered in Hangzhou, China, with additional research operations in Beijing and an international presence that includes offices in the United States.

The company conducts clinical development primarily in China while pursuing international partnerships to expand development and commercialization of its programs globally.

Founding and History

Sciwind Biosciences was founded in 2017 and has raised venture funding to advance a pipeline of metabolic disease therapies.

The company has focused on developing incretin-based medicines, including GLP-1 receptor agonists, which have become a major class of drugs for diabetes and obesity treatment.

In 2025 the company signed a global licensing agreement covering certain metabolic disease programs outside China and South Korea, reflecting growing international interest in its pipeline.

Therapy Areas and Focus

Sciwind’s research programs focus on metabolic and endocrine disorders.

Key areas include:

Obesity and weight management
Type II diabetes
Non-alcoholic steatohepatitis and related metabolic diseases
Viral respiratory infections (exploratory program)

Technology Platforms and Modalities

The company develops therapies using several drug-discovery and formulation platforms.

Key modalities include:

Long-acting peptide therapeutics
Oral peptide delivery technologies
Small-molecule GLP-1 receptor agonists
Biased agonist discovery platforms targeting incretin receptors

These technologies are designed to enable both injectable and oral medicines targeting metabolic pathways.

Key Products and Pipeline

Selected programs include:

Ecnoglutide (XW003), a long-acting GLP-1 receptor agonist developed for obesity and type II diabetes; the drug completed Phase III trials and received regulatory approval in China for chronic weight management.
XW004, an oral peptide GLP-1 analog in Phase I development.
XW014, an oral small-molecule GLP-1 receptor agonist in early clinical testing.
Additional amylin receptor agonists and incretin-pathway therapies under development.

Key Personnel

Hai Pan, Founder and Chief Executive Officer
Weidong Zhong, President and Chief Strategy Officer

Strategic Partnerships

Sciwind has entered partnerships to expand commercialization and global development of its therapies.

Key collaborations include:

Pfizer China, which obtained commercialization rights for ecnoglutide in mainland China.
Verdiva Bio, which licensed global rights outside China and South Korea for certain metabolic-disease programs in a deal with potential milestone payments exceeding $2 billion.

These partnerships support international development and commercialization of Sciwind’s incretin-based therapies.

FAQ Section

Sciwind focuses on therapies targeting metabolic diseases, particularly incretin-based drugs that regulate glucose metabolism and appetite. Many of its programs target GLP-1 and related receptors involved in energy balance and insulin secretion.

GLP-1 receptor agonists stimulate insulin secretion, reduce appetite and slow gastric emptying. These effects make them effective treatments for both diabetes and obesity, and they have become one of the fastest-growing drug classes in metabolic medicine.

Ecnoglutide is Sciwind’s lead product and represents a new type of GLP-1 receptor agonist designed with biased signaling properties. Clinical trials demonstrated significant weight-loss and metabolic benefits, leading to regulatory approval in China for chronic weight management.

The company focuses on next-generation incretin therapies, including biased GLP-1 receptor agonists and oral formulations. These approaches aim to improve efficacy, dosing convenience or tolerability compared with earlier injectable therapies.

Sciwind relies on licensing and commercialization partnerships to expand beyond China. Agreements with international pharmaceutical companies allow the company to develop and market its therapies in global markets while sharing development costs.

The obesity-treatment market has expanded rapidly with the success of GLP-1 therapies such as semaglutide and tirzepatide. Companies like Sciwind are developing next-generation incretin therapies that may offer differentiated efficacy or delivery methods.

Key developments include:

commercialization progress for ecnoglutide in China
clinical development of oral incretin therapies
additional global licensing agreements or regulatory approvals for metabolic disease programs.

Want to Update your Company's Profile?